Skip to main content
SpringerLink
Log in

All Oral HCV Therapies of the Future

  • Hepatitis C: Therapeutics (MP Manns and T von Hahn, Section editors)
  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

Hepatitis C virus (HCV) therapy has revolved around pegylated interferon-alpha (PEG IFN) and ribavirin (RBV), with the recent addition of the direct-acting antivirals (DAA), telaprevir or boceprevir, to the regimen for genotype 1 patients. Further progress has been made with the identification of multiple targets, allowing for additional DAAs, including other protease inhibitors, NS5A inhibitors and NS5B polymerase inhibitors. Initial studies have shown these drugs to provide more effective therapy than the current standard of care when combined with PEG IFN and RBV. More recently, however, even without PEG IFN, combinations of DAAs have been shown to allow for shorter treatment duration, increased efficacy, and better safety profiles. These regimens have the potential to allow HCV to be eradicated with all oral therapy in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently have been highlighted as: • Of importance •• Of major importance

  1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013.

  2. EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.

    Article  Google Scholar 

  3. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int. 2013;33:93–104.

    Article  PubMed  CAS  Google Scholar 

  4. Hezode C, Dorivol C, Zoulim F, et al. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 497 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. Hepatology. 2012;56(Suppl):217A.

    Google Scholar 

  5. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376:1467–75.

    Article  PubMed  CAS  Google Scholar 

  6. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis c genotype 1. NEJM. 2012;266:216–24.

    Article  Google Scholar 

  7. •• Gane EJ, Stedman CA, Hyaland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. NEJM. 2013;368:34–44. One of the initial studies with sofosbuvir, which demonstrated possibility of high SVR rates with all oral DAA regimen.

    Article  PubMed  CAS  Google Scholar 

  8. Lin C. Hepatitis C viruses: genomes and molecular biology. In: Tan SL, editor. Norkfolk; 2006. Chapter 6.

  9. Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second generation protease inhibitors. Liver Int. 2013;33:80–4.

    Article  PubMed  CAS  Google Scholar 

  10. Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol.

  11. Poenisch M, Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis. 2010;30:333–47.

    Article  PubMed  CAS  Google Scholar 

  12. Koch U, Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem. 2007;7:1302–29.

    Article  PubMed  CAS  Google Scholar 

  13. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology. 2013.

  14. McCown MF, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother. 2008;52:1604–12.

    Article  PubMed  CAS  Google Scholar 

  15. Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC 435) Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Naïve Patients: Results from QUEST-1, A Phase III Trial. 48th Annual Meeting of the European Association for the Study of the Liver, Abstract 1425; 2013.

  16. Manns M, Marcellin P, Poordad F, et al. Simeprevir (TMC 435) Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Naïve Patients: Results from QUEST-2, A Phase III Trial. 48th Annual Meeting of the European Association for the Study of the Liver, Abstract 1413; 2013.

  17. Lawitz E, Forns X, Zeuzem S, et al. Simeprevir (TMC 435) Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype-1 Infection in Patients Who Relapsed After Previous Interferon Based Therapy: Results from PROMISE, A Phase III Trial. Digestive Disease Week, Abstract 869; 2013.

  18. Ferenci P, Asselah T, Foster GR, et al. Faldaprevir plus Pegylated Interferon alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment Naïve Patients: Final Results from STARTVerso1, A Randomised, Double-Blind, Placebo-Controlled Phase III Trial. 48th Annual Meeting of the European Association for the Study of the Liver, Abstract 1416, 2013.

  19. •• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. NEJM. 2013;368:1878–87. One of only few phase 3 studies for all oral therapy. Results demonstrated noninferiority of sofosbuvir and ribavirin compared to current standard of care for genotype 2 and 3 patients.

    Article  PubMed  CAS  Google Scholar 

  20. •• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. NEJM. 2013;368:1867–77. One of only few phase 3 studies for all oral therapy. Results stressed the difference between genotype 2 and genotype 3 HCV treatment.

    Article  PubMed  CAS  Google Scholar 

  21. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55:742–8.

    Article  PubMed  CAS  Google Scholar 

  22. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655–62.

    Article  PubMed  CAS  Google Scholar 

  23. Lalezari JP, Nelson DR, Hyland RH, et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naïve patients with HCV infection: the QUANTUM study. J Hepatol. 2013;58:S346.

    Article  Google Scholar 

  24. Osinusi A, et al. High efficacy of sofosbuvir with weight-based ribavirin for 24 weeks in difficult-to-treat patients. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, abstract 157LB; 2013.

  25. •• Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. NEJM. 2013;368:45–53. Important study demonstrating importance of IFN-nonresponsiveness in efficacy with all oral DAA regimens.

    Article  PubMed  CAS  Google Scholar 

  26. Zeuzem S, Soriano V, Asselah T, et al. Interferon (IFN)-free combinationtreatment with HCV NS3/4A protease inhibitor BI 201335 and the non-nucleoside NS5B inhibitor BI 207127 +/− ribavirin (R): final results of SOUND-C2 and predictors of response. Hepatology. 2012;56(Suppl):308A–9A.

    Google Scholar 

  27. • Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 abd ribavirin achieves SVR rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype 1 infection. Hepatology. 2012;56(Suppl):306A. Important study showing high SVR rates in previous null responders.

    Google Scholar 

  28. Abbvie. Press Release. New Data from Abbvie’s Phase IIB AVIATOR Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1. April 23, 2013.

  29. • Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Sustained virologic response with daclatasvir plus sofosbuvir +/− ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir. J Hepatol. 2013;58:S570. Important study showing that previous failure of treatment with a protease inhibitor does not preclude SVR with another DAA regimen.

    Article  Google Scholar 

  30. Gane EJ, Stedman CA, Hyland RH, et al. All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: The ELECTRON Study. 48th Annual Meeting of the European Association for the Study of the Liver, Abstract 14, 2013.

  31. Gilead Sciences. Press Release. May 2, 2013.

  32. Lawitz E, Ghalib R, Rodriguez-Torres M. SVR4 Results of a Once Daily Regimen of Simeprevir (TMC435) Plus Sofosbuvir (GS-7977) with or without Ribavirin (RBV) in HCV GT 1 Null Responders. Digestive Disease Week. Orlando, May 18–21, 2013. Abstract Sa2073.

  33. Everson GT, Sims KD, Rodriguez-Torres M, et al. Interim analysis of an interferon (IFN)- and ribavirin (RBV)-free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 in treatment-naïve, hepatitis C virus genotype 1-infected patients. J Hepatol. 2013;58:S573.

    Article  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Ira Jacobson is a paid consultant for Abbvie, Achillion, Boehringer Ingelheim, Bristol Myers Squibb, Enanta, Gilead, GlaxoSmithKline, Idenix, Kadmon, Novartis, Presidio, Roche/Genentech, Schering/Merck, Tobotec/Janssen, and Vertex. His institution has grants and pending grants from Abbvie, Achillion, Boehringer Ingelheim, Gilead, Novartis, Pfizer, Roche/Genentech, Schering/Merck, Tobotec/Janssen, and Vertex, and receives money on his behalf for Speakers Bureaus from Bristol Myers Squibb, Gilead, Roche/Genentech, and Vertex.

Sonal Kumar declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by either of the authors.

Author information

Authors and Affiliations

  1. Weill Cornell Medical College, 1305 York Avenue, 4th Floor, New York, NY, 10021, USA

    Sonal Kumar & Ira Jacobson

Authors
  1. Sonal Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ira Jacobson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonal Kumar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, S., Jacobson, I. All Oral HCV Therapies of the Future. Curr Hepatitis Rep 12, 214–219 (2013). https://doi.org/10.1007/s11901-013-0190-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-013-0190-6

Keywords

Search

Navigation